HER2-directed Biosimilar in Breast Cancer: Real World ePRO (OGIPRO)
HER2-directed Biosimilar OgivriTM in Breast Cancer: Real World Observational Trial for the Description of Quality of Life and Outcome Using ePRO (OGIPRO- Trial)
Sponsor: OnkoZentrum Zürich AG
Listed as NCT05234021, this observational or N/A phase trial focuses on Biosimilar and HER2-positive Breast Cancer and remains completed. Sponsored by OnkoZentrum Zürich AG, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2024 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Nov 2022 — May 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
Mar 2022 — Nov 2022 [monthly]
Recruiting
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OnkoZentrum Zürich AG
- Palleos Healthcare GmbH
- University of Zurich
For direct contact, visit the study record on ClinicalTrials.gov .